SMMT241004P25500
- 0.00
- 0.000.00%
Summit Therapeutics Newsroom
Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23
Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19
Summit Therapeutics Analyst Ratings
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $40
Stifel Nicolaus Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $19
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $19
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $25
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics' Ivonescimab Outperforms in Trials, Earning Buy Rating and Higher Target Price
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $30
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Summit Therapeutics' Ivonescimab Poised to Outperform KEYTRUDA: A Strong Buy Rating
Summit Therapeutics Analyst Ratings